Drug news

CHMP refuses to recommend approval to Uplyso(Pfizer)for Gaucher Disease

Read time: 1 mins

Last updated:22nd Jun 2012

Published:22nd Jun 2012

Source: Pharmawand

The Committee for Medicinal Products for Human Use (CHMP) will not recommend approval to Uplyso (taliglucerase alfa) from Protalix/Pfizer for long-term enzyme replacement therapy for adults with Type 1 Gaucher disease because the drug works in the same way as Vpriv (velaglucerase alfa) from Shire and as Vpriv is an orphan drug it has 10 years exclusivity

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

CHMP positive recommendation to change to marketing authorisation of Triumeq (abacavir sulfate / dolutegravir sodium / lamivudine) to treat HIV infections.-ViiV HealthCare

1 mins

Drug news

CHMP positive recommendation to change the marketing authorisation of Sirturo (bedaquiline) in patients with pulmonary tuberculosis.- Jansssen- Cilag (J&J)

On 25 April 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Sirturo (bedaquiline). The marketing authorisation holder for this medicinal product is Janssen-Cilag International NV.

1 min

Drug news

CHMP positive recommendation to extend the marketing authorisation of Alecensa (alectinib hydrochloride).- Roche.

1 min

See all news